← Back to Clinical Trials
Recruiting NCT07190170

NCT07190170 Time Restricted Eating for WeIght LoSs MainTenance-2

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07190170
Status Recruiting
Phase
Sponsor NYU Langone Health
Condition Weight Loss
Study Type INTERVENTIONAL
Enrollment 110 participants
Start Date 2025-10-01
Primary Completion 2028-01-01

Eligibility & Interventions

Sex All sexes
Min Age 25 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
TREWeight-Loss Maintenance Advice

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 110 participants in total. It began in 2025-10-01 with a primary completion date of 2028-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The TWIST 2.0 Study is a 12-month, 2-arm RCT in adults with recent weight loss. We will examine the efficacy of TRE on weight (Aim 1a) and fat mass (Aim 1b) regain, and describe changes in subjective appetite following a mixed-meal tolerance test (Exploratory).

Eligibility Criteria

Inclusion Criteria: * ≥5% non-surgical weight loss in the last 3 mos; * current BMI 20.5-45 mg/kg2; * between the ages 25 to 65 years old; * own a smartphone or willing to use a smartphone if provided for self-monitoring. For in-person screening, eligible participants will provide signed informed consent and have their temporal eating patterns measured. Exclusion Criteria: * pregnant, trying to get pregnant or breastfeeding; * previous or planned bariatric surgery; * previous or current history of eating disorder; * ongoing participation in another weight-management research study; * continued participation in a weight loss program other than the proposed study; * currently on appetite suppressants; * currently following intermittent fasting; or skipping meals; * eating window \<11h 59min/day; * perform overnight shift work more than once a week; * work that includes travel across one or more time zones; * taking medications that affect body weight or would preclude TRE; * unable or unwilling to provide informed consent; * unable to participate meaningfully in the intervention (e.g., uncorrected sight and hearing impairment); * unwilling to accept randomization assignment; * unable to log at least 2 meals into the smartphone app for 70% (\~20 days) during of the run-in period; * have type 1 or type 2 diabetes, or other conditions that would preclude restricted eating windows; * narcolepsy, * \>2.5 kg additional weight loss during run-in phase (weight regain is not an exclusion criteria); * is non-English speaking (the mCC app is currently only available in English).

Contact & Investigator

Central Contact

Collin Popp

✉ Collin.popp@nyulangone.org

📞 646-501-3427

Principal Investigator

Collin Popp

PRINCIPAL INVESTIGATOR

NYU Langone Health

Frequently Asked Questions

Who can join the NCT07190170 clinical trial?

This trial is open to participants of all sexes, aged 25 Years or older, up to 65 Years, studying Weight Loss. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07190170 currently recruiting?

Yes, NCT07190170 is actively recruiting participants. Contact the research team at Collin.popp@nyulangone.org for enrollment information.

Where is the NCT07190170 trial being conducted?

This trial is being conducted at New York, United States.

Who is sponsoring the NCT07190170 clinical trial?

NCT07190170 is sponsored by NYU Langone Health. The principal investigator is Collin Popp at NYU Langone Health. The trial plans to enroll 110 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology